Boehringer Ingelheim announced the recipients of the 2019 Advancement in Equine Research Awards at the recent American Association of Equine Practitioners Annual Convention in Denver.
Five proposals focusing on equine infectious respiratory disease and equine asthma syndrome were selected. Recipients include the following:
- Efficacy of disinfection of endoscopes contaminated with Streptococcus equi subsp. equi Laurie Beard, DVM, MS, DACVIM, Kansas State University, Manhattan, KS
- Nebulized glycosylated-caffeic acid phenylether ester attenuation of particulates-induced airway inflammation in horses Jessica Rutledge, BVetMed MRCVS, Oklahoma State University, Stillwater, OK
- The association of equine asthma and obesity in horses Michelle Coleman, DVM, PhD, DACVIM, Texas A&M University, College Station, TX
- Comparative immune responses to modified-live and killed EHV-1 vaccines in weanling foals Nicola Pusterla, DVM, PhD, DACVIM, UC Davis, Davis, CA
- Development of a portable pulmonary function test for equine asthma Melissa R. Mazan, DVM, DACVIM, Tufts University, North Grafton, MA
Each award recipient will receive $15,000 in support of their research.
Since 2011, Boehringer Ingelheim has given more than $620,000 to advancing the knowledge of equine disease, including the $75,000 in grants being awarded this year.
“As a global leader in equine health, Boehringer Ingelheim is committed to supporting equine research and its role in helping understand, diagnose and prevent disease,” said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for Boehringer Ingelheim. “With these research awards, we hope to help make great strides in the industry’s ability to address equine respiratory disease and equine asthma syndrome.”
The Equine Research Review Board, an independent group of equine veterinarians and researchers, selects the recipients of the Advancement in Equine Research Awards annually. Board members for the 2019 award selection process included:
- Tom Divers, DVM, DACVIM, DACVECC
- Rob Franklin, DVM, DACVIM
- Heather Knych, DVM, PhD, DACVCP
- Nathan Slovis, DVM, DACVIM, CHT
- Julie Wilson, DVM, DACVIM
Veterinarians, diagnosticians and public and private researchers in the United States, Canada and Mexico are eligible to submit proposals.
For more information about the Advancement in Equine Research Awards, visit this website.
About the Equine Business of Boehringer Ingelheim
As the global leader in equine health, Boehringer Ingelheim has a main goal to improve equine patients’ health and quality of life. We are dedicated to providing the latest product technology for the treatment and prevention of disease in horses. Learn more about our product portfolio and what we can offer the veterinary community by visiting https://www.bi-vetmedica.com/species/equine.html.
About Boehringer Ingelheim Animal Health USA, Inc.
Boehringer Ingelheim is the second-largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales ofaround $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringeringelheim.com or in the company’s annual report at http://annualreport.boehringeringelheim.com.
